These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 16870436)

  • 1. Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors.
    Atwal KS; O'Neil SV; Ahmad S; Doweyko L; Kirby M; Dorso CR; Chandrasena G; Chen BC; Zhao R; Zahler R
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4796-9. PubMed ID: 16870436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist.
    Tagat JR; McCombie SW; Nazareno D; Labroli MA; Xiao Y; Steensma RW; Strizki JM; Baroudy BM; Cox K; Lachowicz J; Varty G; Watkins R
    J Med Chem; 2004 May; 47(10):2405-8. PubMed ID: 15115380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
    Quan ML; Lam PY; Han Q; Pinto DJ; He MY; Li R; Ellis CD; Clark CG; Teleha CA; Sun JH; Alexander RS; Bai S; Luettgen JM; Knabb RM; Wong PC; Wexler RR
    J Med Chem; 2005 Mar; 48(6):1729-44. PubMed ID: 15771420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel class of sodium/calcium exchanger inhibitors: design, synthesis, and structure-activity relationships of 4-phenyl-3-(piperidin-4-yl)-3,4-dihydro-2(1H)-quinazolinone derivatives.
    Hasegawa H; Muraoka M; Matsui K; Kojima A
    Bioorg Med Chem Lett; 2006 Feb; 16(3):727-30. PubMed ID: 16249082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 3-aminopiperidines as potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitors.
    Cox JM; Harper B; Mastracchio A; Leiting B; Sinha Roy R; Patel RA; Wu JK; Lyons KA; He H; Xu S; Zhu B; Thornberry NA; Weber AE; Edmondson SD
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4579-83. PubMed ID: 17562364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-Substituted-(5-arylfuran-2-ylcarbonyl)guanidines as NHE-1 inhibitors.
    Lee S; Kim T; Lee BH; Yoo SE; Lee K; Yi KY
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1291-5. PubMed ID: 17189690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of the metabolites of 2-(1-{3-[(6-chloronaphthalen-2-yl)sulfonyl]propanoyl}piperidin-4-yl)-5-methyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one.
    Fujimoto T; Tobisu M; Konishi N; Kawamura M; Tada N; Takagi T; Kubo K
    Bioorg Med Chem; 2009 Dec; 17(23):7993-8002. PubMed ID: 19861238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological activity of 4-[(4-cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as potent and selective farnesyltransferase inhibitors.
    Wang L; Wang GT; Wang X; Tong Y; Sullivan G; Park D; Leonard NM; Li Q; Cohen J; Gu WZ; Zhang H; Bauch JL; Jakob CG; Hutchins CW; Stoll VS; Marsh K; Rosenberg SH; Sham HL; Lin NH
    J Med Chem; 2004 Jan; 47(3):612-26. PubMed ID: 14736242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors.
    Baumgarth M; Beier N; Gericke R
    J Med Chem; 1997 Jun; 40(13):2017-34. PubMed ID: 9207943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
    Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
    J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds.
    Shen DM; Shu M; Willoughby CA; Shah S; Lynch CL; Hale JJ; Mills SG; Chapman KT; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Siciliano SJ; Lyons K; Pivnichny JV; Kwei GY; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller MD; Emini EA
    Bioorg Med Chem Lett; 2004 Feb; 14(4):941-5. PubMed ID: 15012998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1-(1,3-Benzodioxol-5-ylmethyl)-3-[4-(1H-imidazol-1-yl)phenoxy]-piperidine analogs as potent and selective inhibitors of nitric oxide formation.
    Wei RG; Adler M; Davey D; Ho E; Mohan R; Polokoff M; Tseng JL; Whitlow M; Xu W; Yuan S; Phillips G
    Bioorg Med Chem Lett; 2007 May; 17(9):2499-504. PubMed ID: 17368901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.
    Parlow JJ; Burney MW; Case BL; Girard TJ; Hall KA; Hiebsch RR; Huff RM; Lachance RM; Mischke DA; Rapp SR; Woerndle RS; Ennis MD
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6148-56. PubMed ID: 19796941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.
    Ammirati MJ; Andrews KM; Boyer DD; Brodeur AM; Danley DE; Doran SD; Hulin B; Liu S; McPherson RK; Orena SJ; Parker JC; Polivkova J; Qiu X; Soglia CB; Treadway JL; VanVolkenburg MA; Wilder DC; Piotrowski DW
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1991-5. PubMed ID: 19275964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of 5-[(aryl)(1H-imidazol-1-yl)methyl]-1H-indoles: potent and selective aromatase inhibitors.
    Lézé MP; Le Borgne M; Pinson P; Palusczak A; Duflos M; Le Baut G; Hartmann RW
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1134-7. PubMed ID: 16380254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of an N-(2-aminopyridin-4-ylmethyl)nicotinamide derivative: a potent and orally bioavailable NCX inhibitor.
    Kuramochi T; Kakefuda A; Yamada H; Tsukamoto I; Taguchi T; Sakamoto S
    Bioorg Med Chem; 2005 Jun; 13(12):4022-36. PubMed ID: 15911315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.
    Liverton NJ; Bednar RA; Bednar B; Butcher JW; Claiborne CF; Claremon DA; Cunningham M; DiLella AG; Gaul SL; Libby BE; Lyle EA; Lynch JJ; McCauley JA; Mosser SD; Nguyen KT; Stump GL; Sun H; Wang H; Yergey J; Koblan KS
    J Med Chem; 2007 Feb; 50(4):807-19. PubMed ID: 17249648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable.
    Buttar D; Edge M; Emery SC; Fitzek M; Forder C; Griffen A; Hayter B; Hayward CF; Hopcroft PJ; Luke RW; Page K; Stawpert J; Wright A
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4723-6. PubMed ID: 18676144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-[5-Fluoro-3-[4-(2-methyl-1H-imidazol-1-yl)benzyloxy]phenyl]-3,4,5,6- tetrahydro-2H-pyran-4-carboxamide, an orally active inhibitor of 5-lipoxygenase with improved pharmacokinetic and toxicology characteristics.
    Mano T; Okumura Y; Sakakibara M; Okumura T; Tamura T; Miyamoto K; Stevens RW
    J Med Chem; 2004 Jan; 47(3):720-5. PubMed ID: 14736252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability.
    Allerton CM; Barber CG; Beaumont KC; Brown DG; Cole SM; Ellis D; Lane CA; Maw GN; Mount NM; Rawson DJ; Robinson CM; Street SD; Summerhill NW
    J Med Chem; 2006 Jun; 49(12):3581-94. PubMed ID: 16759100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.